{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T17:32:55Z","timestamp":1790530375507,"version":"4.1.0"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Androgen deprivation therapy (ADT) and next-generation androgen receptor pathway inhibitors (ARPI) are increasingly combined with PARP inhibitors (PARPi) in metastatic prostate cancer (mPCa). These treatments have improved outcomes, yet responses remain variable and often lack durability. Single-cell and spatial multi-omics studies indicate that tumor-associated macrophages (TAMs) strongly influence therapeutic response and form a treatment-shaped continuum of states enriched for TREM2 and SPP1 programs, lipid metabolic activity, hypoxia adaptation, and phagocytic checkpoint signaling within the osteogenic cancer-associated fibroblast (CAF) niche. Macrophages also possess functional androgen receptor (AR) activity, which supports an AR-driven myeloid circuit that promotes immune exclusion during ADT or ARPI therapy. PARP inhibitors stimulate cGAS-STING and induce senescence-associated secretory phenotypes (SASP), leading to an initial type I interferon (IFN) response that ultimately transitions to an MDSC-like immunosuppressive phenotype. These processes converge on common mechanisms of phagocytic control through CD47-SIRP\u03b1, MerTK, Axl, CSF1R, and TREM2 and represent therapeutic targets for combination therapies. This review details the combined impact of ADT and PARPi and introduces a multi-omic framework that integrates TREM2 or SPP1 burden, STING activation status, phagocytic checkpoint expression, and HRR or SPOP genotype into a Myeloid Lymphatic Composite Score (MLCS). The MLCS is a scoring tool to assist in timing and selecting therapeutic combinations of ARPI with TREM2 or CSF1R blockade, PARPi with STING modulation, and ARPI with anti-CD47 therapy. Integrating mechanistic and translational data provides a foundation for biomarker-guided regimens capable of converting prostate cancer from an immune-cold disease to an immune-responsive state.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1745168","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:44:48Z","timestamp":1766040288000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["TAM Plasticity under androgen deprivation therapy and PARP inhibition in prostate cancer: a multi-omics perspective"],"prefix":"10.3389","volume":"16","author":[{"given":"Shuangming","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (Propel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.115932","article-title":"Orchestration of tumor-associated macrophages in the tumor cell-macrophage-cd8(+) T cell loop for cancer immunotherapy","volume":"21","author":"He","year":"2025","journal-title":"Int J Biol Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1038\/s41467-025-62381-x","article-title":"Ar(+)Trem2(+) macrophage induced pathogenic immunosuppression promotes prostate cancer progression","volume":"16","author":"Wang","year":"2025","journal-title":"Nat Commun"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08290-3","article-title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer","volume":"637","author":"Lyu","year":"2025","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3390\/biomedicines13040909","article-title":"Comprehensive integrated analysis reveals the spatiotemporal microevolution of cancer cells in patients with bone-metastatic prostate cancer","volume":"13","author":"Feng","year":"2025","journal-title":"Biomedicines"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.1038\/s41467-020-18313-y","article-title":"Androgen receptor signalling in macrophages promotes trem-1-mediated prostate cancer cell line migration and invasion","volume":"11","author":"Cioni","year":"2020","journal-title":"Nat Commun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2021-1685","article-title":"Abstract 1685: parp\/pi3k inhibitor combination therapy eradicates C-myc-driven murine prostate cancers via cgas\/sting pathway activation within tumor-associated macrophages","volume":"81","author":"Gupta","year":"2021","journal-title":"Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.celrep.2014.08.044","article-title":"Enhancing chemotherapy efficacy in pten-deficient prostate tumors by activating the senescence-associated antitumor immunity","volume":"9","author":"Toso","year":"2014","journal-title":"Cell Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00233","article-title":"Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase iii keylynk-010 trial","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12527","article-title":"The cd47-sirp\u03b1 Signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s12032-023-02153-z","article-title":"Targeting mertk decreases efferocytosis and increases anti-tumor immune infiltrate in prostate cancer","volume":"40","author":"Myers Chen","year":"2023","journal-title":"Med Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.3390\/cancers15194904","article-title":"Hematological toxicities with parp inhibitors in prostate cancer: A systematic review and meta-analysis of phase ii\/iii randomized controlled trials","volume":"15","author":"Bowling","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.Mcr-24-0791","article-title":"Single-cell and spatial transcriptomics reveal a tumor-associated macrophage subpopulation that mediates prostate cancer progression and metastasis","volume":"23","author":"Mei","year":"2025","journal-title":"Mol Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201202367","article-title":"Targeting the androgen receptor with sirna promotes prostate cancer metastasis through enhanced macrophage recruitment via ccl2\/ccr2-induced stat3 activation","volume":"5","author":"Izumi","year":"2013","journal-title":"EMBO Mol Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12964-020-00589-8","article-title":"Ccl2\/ccr2 signaling in cancer pathogenesis","volume":"18","author":"Hao","year":"2020","journal-title":"Cell Commun Signal"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e13115","DOI":"10.1111\/cpr.13115","article-title":"Role of the ccl2-ccr2 signalling axis in cancer: mechanisms and therapeutic targeting","volume":"54","author":"Xu","year":"2021","journal-title":"Cell Prolif"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8580043","article-title":"The roles of tumor-associated macrophages in prostate cancer","volume":"2022","author":"Han","year":"2022","journal-title":"J Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2018.02.016","article-title":"Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating spdef and activating ccl2","volume":"1864","author":"Tsai","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1038\/s41467-025-59381-2","article-title":"Histone methyltransferase ash1l primes metastases and metabolic reprogramming of macrophages in the bone niche","volume":"16","author":"Meng","year":"2025","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s11658-023-00450-z","article-title":"Single-cell omics traces the heterogeneity of prostate cancer cells and the tumor microenvironment","volume":"28","author":"Yu","year":"2023","journal-title":"Cell Mol Biol Lett"},{"key":"B22","doi-asserted-by":"publisher","first-page":"9949","DOI":"10.1038\/s41467-024-54364-1","article-title":"Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer","volume":"15","author":"Kiviaho","year":"2024","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"7414","DOI":"10.1038\/s41467-024-51450-2","article-title":"Convergent alterations in the tumor microenvironment of myc-driven human and murine prostate cancer","volume":"15","author":"Graham","year":"2024","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12943-025-02481-w","article-title":"Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy","volume":"24","author":"Coelho","year":"2025","journal-title":"Mol Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"20220116","DOI":"10.3390\/cancers14020440","article-title":"Macrophages as a therapeutic target in metastatic prostate cancer: A way to overcome immunotherapy resistance","volume":"14","author":"Martori","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231221337","article-title":"Development of parp inhibitors in advanced prostate cancer","volume":"16","author":"Bourlon","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e003744","DOI":"10.1136\/jitc-2021-003744","article-title":"Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes","volume":"10","author":"Trigos","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","article-title":"How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer","volume":"24","author":"Stultz","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-23-1093","article-title":"Intratumoral trex1 induction promotes immune evasion by limiting type I ifn","volume":"12","author":"Toufektchan","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1661","article-title":"Hydrolysis of 2\u20193\u2019-cgamp by enpp1 and design of nonhydrolyzable analogs","volume":"10","author":"Li","year":"2014","journal-title":"Nat Chem Biol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e9188","DOI":"10.1371\/journal.pone.0009188","article-title":"A human-like senescence-associated secretory phenotype is conserved in mouse cells dependent on physiological oxygen","volume":"5","author":"Copp\u00e9","year":"2010","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1038\/s41467-019-10460-1","article-title":"Exploiting interconnected synthetic lethal interactions between parp inhibition and cancer cell reversible senescence","volume":"10","author":"Fleury","year":"2019","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2025.149774","article-title":"Therapy-induced senescence in prostate cancer: mechanisms, therapeutic strategies, and clinical implications","volume":"972","author":"Bacca","year":"2025","journal-title":"Gene"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0156-2","article-title":"Unmasking senescence: context-dependent effects of sasp in cancer","volume":"19","author":"Faget","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"825","DOI":"10.3390\/biomedicines11030825","article-title":"Hif-1\u03b1-overexpressing mesenchymal stem cells attenuate colitis by regulating M1-like macrophages polarization toward M2-like macrophages","volume":"11","author":"Zhu","year":"2023","journal-title":"Biomedicines"},{"key":"B36","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12943-025-02436-1","article-title":"Targeting cxcr2 in prostate cancer cells can block cd47-sirp\u03b1 Interaction and reverse M2 macrophage polarization in the tme","volume":"24","author":"Sun","year":"2025","journal-title":"Mol Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s42003-023-04615-6","article-title":"The DNA damage response pathway regulates the expression of the immune checkpoint cd47","volume":"6","author":"Ghantous","year":"2023","journal-title":"Commun Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-23-2135","article-title":"Human tumor-associated macrophages and neutrophils regulate antitumor antibody efficacy through lethal and sublethal trogocytosis","volume":"84","author":"Singhal","year":"2024","journal-title":"Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nature13638","article-title":"Tumour-infiltrating gr-1+ Myeloid cells antagonize senescence in cancer","volume":"515","author":"Di Mitri","year":"2014","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01232-z","article-title":"Targeting of tams: can we be more clever than cancer cells","volume":"21","author":"Kzhyshkowska","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-14-0992","article-title":"Csf1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy","volume":"75","author":"Escamilla","year":"2015","journal-title":"Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12885-025-13481-w","article-title":"Dual role of cathepsin S in cutaneous melanoma: insights from mendelian randomization and bioinformatics analysis","volume":"25","author":"Zhou","year":"2025","journal-title":"BMC Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.Mcr-17-0665","article-title":"Cholesterol esterification inhibition suppresses prostate cancer metastasis by impairing the wnt\/\u03b2-catenin pathway","volume":"16","author":"Lee","year":"2018","journal-title":"Mol Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1186\/s12885-025-14246-1","article-title":"Interplay of disulfidptosis and the tumor microenvironment across cancers: implications for prognosis and therapeutic responses","volume":"25","author":"Xu","year":"2025","journal-title":"BMC Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-020-00916-z","article-title":"Cgas-sting, an important pathway in cancer immunotherapy","volume":"13","author":"Jiang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.Mcr-14-0173","article-title":"Synergistic loss of prostate cancer cell viability by coinhibition of hdac and parp","volume":"12","author":"Chao","year":"2014","journal-title":"Mol Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccell.2018.01.019","article-title":"Brd4 inhibition is synthetic lethal with parp inhibitors through the induction of homologous recombination deficiency","volume":"33","author":"Sun","year":"2018","journal-title":"Cancer Cell"},{"key":"B48","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12943-024-02013-y","article-title":"N6-methyladenosine-modified senp1, identified by igf2bp3, is a novel molecular marker in acute myeloid leukemia and aggravates progression by activating akt signal via de-sumoylating hdac2","volume":"23","author":"Wen","year":"2024","journal-title":"Mol Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.32604\/or.2025.071708","article-title":"Cd47-targeted therapy in cancer immunotherapy: at a crossroads of promise and challenge","volume":"33","author":"Guo","year":"2025","journal-title":"Oncol Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-22-0583","article-title":"A phase I study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (Mcrpc) with bone metastases (Comrade)","volume":"22","author":"Pan","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-22-2526","article-title":"Phase I study of niraparib in combination with radium-223 for the treatment of metastatic castrate-resistant prostate cancer","volume":"29","author":"Quinn","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2023.08. 28.555056","DOI":"10.1101\/2023.08.28.555056","article-title":"Integration of multiple spatial omics modalities reveals unique insights into molecular heterogeneity of prostate cancer","author":"Zhang","year":"2023","journal-title":"Biorxiv"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1038\/s41467-018-04724-5","article-title":"Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity","volume":"9","author":"Berglund","year":"2018","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s12672-025-01840-9","article-title":"Identification of gbn5 as a molecular biomarker of pan-cancer species by integrated multi-omics analysis","volume":"16","author":"Guo","year":"2025","journal-title":"Discov Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1459967","article-title":"Exploring the gut microbiome and immunological landscape in kidney cancer: A mendelian randomization analysis","volume":"15","author":"Lv","year":"2024","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.09.005","article-title":"Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment","volume":"39","author":"Kfoury","year":"2021","journal-title":"Cancer Cell"},{"key":"B57","doi-asserted-by":"publisher","first-page":"110132","DOI":"10.1016\/j.celrep.2021.110132","article-title":"Resolving the immune landscape of human prostate at a single-cell level in health and cancer","volume":"37","author":"Tuong","year":"2021","journal-title":"Cell Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn0478","article-title":"Lineage plasticity in prostate cancer depends on jak\/stat inflammatory signaling","volume":"377","author":"Chan","year":"2022","journal-title":"Science"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e2305724","DOI":"10.1002\/advs.202305724","article-title":"Integration analysis of single-cell multi-omics reveals prostate cancer heterogeneity","volume":"11","author":"Bian","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B60","article-title":"Trem2 as an independent predictor of poor prognosis promotes the migration via the pi3k\/akt axis in prostate cancer","volume":"15","author":"Gao","year":"2023","journal-title":"Am J Transl Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e009368","DOI":"10.1136\/jitc-2024-009368","article-title":"Targeting a sting agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy","volume":"12","author":"Al-Janabi","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-23-1439","article-title":"Spop mutations target sting1 signaling in prostate cancer and create therapeutic vulnerabilities to parp inhibitor-induced growth suppression","volume":"29","author":"Geng","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/2473075","article-title":"Evaluation of cd47 in the suppressive tumor microenvironment and immunotherapy in prostate cancer","volume":"2023","author":"Wang","year":"2023","journal-title":"J Immunol Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.55.3875","article-title":"Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: cou-aa-302 results","volume":"33","author":"Morris","year":"2015","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00560-3","article-title":"Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer","volume":"26","author":"Roy","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34708","article-title":"Spatial whole transcriptome profiling of primary tumor from patients with metastatic prostate cancer","volume":"153","author":"Salachan","year":"2023","journal-title":"Int J Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-25-0269","article-title":"Combining spatial transcriptomics, pseudotime, and machine learning enables discovery of biomarkers for prostate cancer","volume":"85","author":"Smelik","year":"2025","journal-title":"Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.718155","article-title":"A fully automatic artificial intelligence system able to detect and characterize prostate cancer using multiparametric mri: multicenter and multi-scanner validation","volume":"11","author":"Giannini","year":"2021","journal-title":"Front Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3390\/biology13100762","article-title":"Contemporary update on clinical and experimental prostate cancer biomarkers: A multi-omics-focused approach to detection and risk stratification","volume":"13","author":"Hachem","year":"2024","journal-title":"Biol (Basel)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31173","article-title":"Bone biopsy protocol for advanced prostate cancer in the era of precision medicine","volume":"124","author":"Sailer","year":"2018","journal-title":"Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1205266","article-title":"High infiltration of cd209(+) dendritic cells and cd163(+) macrophages in the peritumor area of prostate cancer is predictive of late adverse outcomes","volume":"14","author":"Molina","year":"2023","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2018.9152","article-title":"Cxcl9 Promotes Prostate Cancer Progression through Inhibition of Cytokines from T cells","volume":"18","author":"Tan","year":"2018","journal-title":"Mol Med Rep"},{"key":"B73","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jmoldx.2015.12.006","article-title":"Application of a clinical whole-transcriptome assay for staging and prognosis of prostate cancer diagnosed in needle core biopsy specimens","volume":"18","author":"Knudsen","year":"2016","journal-title":"J Mol Diagn"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1080\/15592294.2020.1712876","article-title":"Evaluating liquid biopsies for methylomic profiling of prostate cancer","volume":"15","author":"Silva","year":"2020","journal-title":"Epigenetics"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-023-03660-0","article-title":"Siuro best practice recommendations to optimize brca 1\/2 gene testing from DNA extracted from bone biopsy in mcrpc patients (Brca optimal bone biopsy procedure: bop)","volume":"483","author":"Cimadamore","year":"2023","journal-title":"Virchows Arch"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24269","article-title":"Clinical and genomic features of spop-mutant prostate cancer","volume":"82","author":"Nakazawa","year":"2022","journal-title":"Prostate"},{"key":"B77","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","article-title":"Colony-stimulating factor 1 receptor (Csf1r) inhibitors in cancer therapy","volume":"5","author":"Cannarile","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B78","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12943-025-02355-1","article-title":"Clinical approaches to overcome parp inhibitor resistance","volume":"24","author":"Zou","year":"2025","journal-title":"Mol Cancer"},{"key":"B79","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1186\/s13063-020-04515-8","article-title":"The probio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer","volume":"21","author":"Crippa","year":"2020","journal-title":"Trials"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e175230","DOI":"10.1001\/jamaoncol.2017.5230","article-title":"Comparison between adjuvant and early-salvage postprostatectomy radiotherapy for prostate cancer with adverse pathological features","volume":"4","author":"Hwang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.201700275","article-title":"Bayesian hierarchical classification and information sharing for clinical trials with subgroups and binary outcomes","volume":"61","author":"Chen","year":"2019","journal-title":"Biom J"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1177\/1740774513497539","article-title":"Bayesian hierarchical modeling of patient subpopulations: efficient designs of phase ii oncology clinical trials","volume":"10","author":"Berry","year":"2013","journal-title":"Clin Trials"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1177\/17562872241272929","article-title":"Parp inhibitors alone or in combination for prostate cancer","volume":"16","author":"Fenor de la Maza","year":"2024","journal-title":"Ther Adv Urol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11523-023-01016-x","article-title":"Hematological toxicity of parp inhibitors in metastatic prostate cancer patients with mutations of brca or hrr genes: A systematic review and safety meta-analysis","volume":"19","author":"Maiorano","year":"2024","journal-title":"Target Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03204-2","article-title":"Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial","volume":"30","author":"De Laere","year":"2024","journal-title":"Nat Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-6331572\/v1","article-title":"Plasma cell-free DNA methylation-based prognosis in metastatic castrate-resistant prostate cancer","author":"Wong","year":"2025","journal-title":"Res Sq"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1097\/rli.0000000000001102","article-title":"Multimodal ai combining clinical and imaging inputs improves prostate cancer detection","volume":"59","author":"Roest","year":"2024","journal-title":"Invest Radiol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2020.1777624","article-title":"Trial watch: sting agonists in cancer therapy","volume":"9","author":"Le Naour","year":"2020","journal-title":"Oncoimmunology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1745168\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:44:49Z","timestamp":1766040289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1745168\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":88,"alternative-id":["10.3389\/fimmu.2025.1745168"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1745168","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"article-number":"1745168"}}